Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia

Inclusion Criteria: * Man or woman aged ≥18 years and ≤60 years with a body mass index (BMI) of ≥18.5 and ≤38 m2 * Primary diagnosis of schizophrenia according to DSM-IV-TR™ (codes 295.10, 295.20, 295.30, 295.90) * Clinical Global Impression - Severity of Illness (CGI-S) score ≤4 (moderately ill) at the Screening Visit and Baseline Visit (Day -1) * PANSS total score ≤80 at the Screening Visit and the Baseline Visit (Day -1) * Score of 4 (moderate) of the following PANSS items at the Screening Visit and the Baseline Visit (Day -1): P7 (hostility), G8 (uncooperativeness) * Minimal level of extrapyramidal signs, defined as a score ≤5 (moderately severe) in any of the four Clinical Global Impression of Severity (CGI-S) items of the ESRS-A; parkinsonism, akathisia, dystonia, and tardive dyskinesia at the Screening Visit and the Baseline Visit * Willingness to be hospitalised for approximately 3 weeks after the Baseline Visit (Day -1) Exclusion Criteria: * The patient experienced an acute exacerbation requiring hospitalization within the last 6 months * The patient experienced an acute exacerbation requiring increase in antipsychotic medication (with reference to drug or dose) within the last 4 weeks Other pre-defined inclusion and exclusion criteria may apply